Short traders are more bullish on shares of the company considering the downtick in short interest. The stock realized a fall in short interest of -14.67% as of the latest report on October 13, 2017. Short interest fell from 458,159 to 390,930 over that period. Days to cover decreased from 6.0 to 1.0 and the percentage of shorted shares is 0.04% as of October 13.
The following firms have recently changed their position in AKER. As of the end of the quarter Citadel Advisors LLC had acquired 20,010 shares growing its stake by 190.6%. The value of the investment in (AKER) increased from $20,000 to $55,000 a change of 175.0% for the reporting period. As of quarter end Hsbc Holdings Plc had sold a total of 1,500 shares trimming its position 4.6%. The value of the total investment in Akers Biosciences Inc went from $59,000 to $39,000 a change of $20,000 quarter over quarter.
Blackrock Inc. cut its stake by selling 13,388 shares a decrease of 95.2% as of 06/30/2017. Blackrock Inc. claims 680 shares with a value of $1,000. The total value of its holdings decreased 96.0%. As of quarter end Ubs Group Ag had acquired a total of 8,372 shares growing its holdings by 2,790.7%. The value of the investment in Akers Biosciences Inc went from $1,000 to $11,000 increasing 1,000.0% since the last quarter.
The company is trading down from yesterday’s close of $0.82. It is trading at $0.82 just a bit lower than $0.89, the stock’s 50 day moving average and which is well below the 200 day moving average of $1.17. The 50 day moving average was down by -8.7092% and the 200 day average moved down $-0.36.
As of the latest earnings report the EPS was $-0.42 and is expected to be $-0.25 for the current year with 8,901,000 shares currently outstanding. Next quarter’s EPS is estimated at $0.02 and the next full year EPS is projected to be $0.34.
Akers Biosciences, Inc., launched on March 9, 1989, develops, manufactures and supplies point-of-care screening and testing products designed to bring health-related information to the patient or clinician. The Business’s product offerings and pipeline products focus on delivering diagnostic assistance in a range of healthcare fields/specialties, including cardiology/emergency medicine, metabolism/nutrition, diabetes, respiratory diseases and infectious diseases detection, as well as for on and off-the-job alcohol safety initiatives. The Business’s primary focus is the development and sale of disposable diagnostic testing devices that can be performed in minutes, to facilitate time sensitive therapeutic decisions. The Business’s main products are a disposable breathalyzer test that measures the blood alcohol content of the user, a rapid test detecting the antibody causing an allergic reaction to Heparin and a disposable breathalyzer test that measures Free Radical activity in the human body..